UBS Group set a $6.00 target price on Selecta Biosciences (NASDAQ:SELB) in a research note released on Friday morning, www.stocktargetadvisor.com reports. The brokerage currently has a hold rating on the stock.
SELB has been the subject of several other research reports. Janney Montgomery Scott reissued a buy rating on shares of Selecta Biosciences in a research report on Tuesday, October 23rd. BidaskClub lowered shares of Selecta Biosciences from a buy rating to a hold rating in a research report on Friday, October 5th. Mizuho reissued a buy rating and issued a $30.00 price target on shares of Selecta Biosciences in a research report on Monday, November 5th. Stifel Nicolaus initiated coverage on shares of Selecta Biosciences in a research report on Friday, September 14th. They issued a buy rating and a $24.00 price target for the company. Finally, Zacks Investment Research raised shares of Selecta Biosciences from a sell rating to a hold rating in a research report on Wednesday, October 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. Selecta Biosciences currently has an average rating of Hold and a consensus target price of $23.83.
NASDAQ:SELB traded down $0.29 during mid-day trading on Friday, hitting $5.51. The company’s stock had a trading volume of 347,760 shares, compared to its average volume of 444,699. Selecta Biosciences has a fifty-two week low of $4.74 and a fifty-two week high of $16.55. The company has a quick ratio of 4.96, a current ratio of 4.96 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $129.90 million, a PE ratio of -1.72 and a beta of 0.91.
Selecta Biosciences (NASDAQ:SELB) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.08. On average, research analysts expect that Selecta Biosciences will post -3.07 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers increased its holdings in shares of Selecta Biosciences by 43.7% during the second quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock worth $222,000 after buying an additional 5,103 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Selecta Biosciences by 37.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 33,700 shares of the company’s stock worth $447,000 after buying an additional 9,100 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Selecta Biosciences by 27.2% during the second quarter. Bank of New York Mellon Corp now owns 47,273 shares of the company’s stock worth $626,000 after buying an additional 10,114 shares in the last quarter. Proxima Capital Management LLC acquired a new stake in shares of Selecta Biosciences during the second quarter worth approximately $1,075,000. Finally, Millennium Management LLC acquired a new stake in shares of Selecta Biosciences during the second quarter worth approximately $1,583,000. 48.63% of the stock is owned by institutional investors.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Featured Story: Balance Sheet
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.